1. A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma. Issue 11 (27th November 2021) Authors: Collins, Graham P.; Eyre, Toby A.; Schmitz-Rohmer, Debora; Townsend, William; Popat, Rakesh; Giulino-Roth, Lisa; Fields, Paul A.; Krasniqi, Fatime; Soussain, Carole; Stathis, Anastasios; Andjelkovic, Nebojsa; Cunningham, David; Mandic, Danijela; Radulovic, Sinisa; Tijanic, Ivan; Horowitz, Netanel... Journal: HemaSphere Issue: Volume 5:Issue 11(2021) Page Start: e656 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗